

Sherri Z Millis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4812694/publications.pdf>

Version: 2024-02-01

38
papers

660
citations

623734

14
h-index

580821

25
g-index

39
all docs

39
docs citations

39
times ranked

1330
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 4018-4025.	1.8	118
2	Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. <i>Modern Pathology</i> , 2019, 32, 1593-1604.	5.5	74
3	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-23.	3.0	63
4	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	51
5	BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma. <i>Oncologist</i> , 2019, 24, 973-979.	3.7	49
6	Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. <i>Cancer</i> , 2019, 125, 1185-1199.	4.1	36
7	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11001-11001.	1.6	26
8	BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	3.0	24
9	Genomic Landscape of Appendiceal Neoplasms. <i>JCO Precision Oncology</i> , 2018, 2, 1-18.	3.0	23
10	Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. <i>Oncologist</i> , 2019, 24, 989-996.	3.7	23
11	Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. <i>Cancer Research</i> , 2017, 77, 6313-6320.	0.9	22
12	Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart. <i>Oncologist</i> , 2019, 24, e142-e145.	3.7	22
13	Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma. <i>JAMA Network Open</i> , 2019, 2, e1912416.	5.9	19
14	Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. <i>Oncologist</i> , 2021, 26, e78-e89.	3.7	18
15	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2028-2036.e2.	0.7	17
16	Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target. <i>Npj Precision Oncology</i> , 2021, 5, 43.	5.4	14
17	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist</i> , 2020, 25, e39-e47.	3.7	13
18	Recurrent secondary genomic alterations in desmoplastic small round cell tumors. <i>BMC Medical Genetics</i> , 2020, 21, 101.	2.1	10

#	ARTICLE	IF	CITATIONS
19	Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation. <i>Case Reports in Oncology</i> , 2017, 10, 548-552.	0.7	9
20	Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma Specimens. <i>JCO Precision Oncology</i> , 2020, 4, 176-182.	3.0	9
21	Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. <i>Npj Precision Oncology</i> , 2022, 6, 29.	5.4	6
22	Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. <i>Oncologist</i> , 2021, 26, e715-e718.	3.7	5
23	Identification of novel fumarate hydratase gene alterations in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11585-11585.	1.6	3
24	Frequency of genetic homologous recombination (HR) alterations in metastatic cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21033-e21033.	1.6	3
25	Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4555-4555.	1.6	1
26	Refractory testicular pure seminoma (PS) and non-seminomatous(NS) germ cell tumors (GCT): A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 565-565.	1.6	1
27	Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11576-11576.	1.6	1
28	Genomic alterations and associated pathway abnormalities in Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11532-11532.	1.6	0
29	Comprehensive genomic sequencing of appendiceal cancer tumors to identify different genomic alterations by subtype, novel treatment opportunities, and improved outcomes.. <i>Journal of Clinical Oncology</i> , 2017, 35, 599-599.	1.6	0
30	<i>FGFR3</i> Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4531-4531.	1.6	0
31	Ductal and acinar carcinomas of the prostate: A comparative comprehensive genomic profiling study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 271-271.	1.6	0
32	Genomic findings in adenocarcinoma of the urinary bladder.. <i>Journal of Clinical Oncology</i> , 2019, 37, 132-132.	1.6	0
33	Histone H3 modifying genes may serve as a predictive marker for metastasis in synovial sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11058-11058.	1.6	0
34	Secondary genomic alterations in Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11024-11024.	1.6	0
35	Determinants of secondary alterations in <i>WWTR1-CAMTA1</i> fusion epithelioid hemangioendothelioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11045-11045.	1.6	0
36	Multiscale omic assessment of EWSR1-NFATc2 fusion positive sarcomas to identify conserved fusion breakpoint and activation of the mTOR pathway.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23536-e23536.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Cyclin pathway genomic alterations across 5,356 prostate cancers.. Journal of Clinical Oncology, 2020, 38, 179-179.	1.6	0
38	Landscape of cyclin pathway genomic alterations across 7,207 non-prostate genitourinary tumors.. Journal of Clinical Oncology, 2020, 38, 549-549.	1.6	0